Trials / NCT01773278
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
Status unknown Phase 2 Supplement / diet, Drug / neuroprotection
- Sponsor
- University of Colorado, Denver
- Treatment
- Antioxidants; Cholesterol
- Gene
- Not stated
- Conditions
- Smith-Lemli-Opitz Syndrome, Cone-Rod Dystrophy, Hearing Loss
- Ages
- Any to 65 Years
- Enrollment
- 100 participants
- Started
- 2008-12
- Main results expected
- 2025-12
- Results posted
- Not yet
- Record last updated
- 2024-05-08
What the study is testing
Patients with biochemically confirmed SLOS are being treated with cholesterol supplementation and antioxidant medication. They are carefully monitored with visits to clinic, laboratory testing including cholesterol and 7-dehydrocholesterol levels, vitamin levels, blood counts and liver and kidney function. On a serial basis, no more often than once a year, the patients undergo a series of tests under anesthesia, including electroretinogram (ERG), brainstem audiometry (ABR), and ophthalmologic exam under anesthesia to follow pigmentary retinopathy.
Where it runs
United States (1)
- Children's Hospital Colorado, Aurora, Colorado (recruiting now)